Willow Biosciences Announces Collaboration with Biopharma Company
The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients.
Willow Biosciences, a leading biotechnology company focused on revolutionizing sustainable, functional ingredients, announced a collaboration with a Nasdaq-listed biopharma company on Aug. 21, 2023 to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs), according to a press release.
The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients. Further, the initial program plans to focus on the practicability of creating a biobased pathway and advance development toward implementation at commercial scale, which is expected to last approximately two months.
The partner’s name and other information are not being shared currently due to the competitive nature of the targeted ingredient applications, according to the press release.
“We are honored to have been selected by such a forward-thinking biopharmaceutical company to jointly explore innovative pathways toward the development of sustainably sourced intermediates and APIs,” said Dr. Chris Savile, Willow’s president & CEO, in a press release. “If successful, we believe that by leveraging biobased routes, these ingredients essential for human health can be made more broadly available while providing a solution for overseas supply chain issues that can increase cost and potentially create shortages.”
Source: Willow Bio
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.
